<DOC>
	<DOCNO>NCT02495974</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness enzalutamide patient metastatic castration resistant prostate cancer ( mCRPC ) clinical practice set measured time treatment failure define time baseline ( treatment initiation ) treatment discontinuation enzalutamide reason include disease progression , skeletal related event , treatment toxicity , patient preference , death .</brief_summary>
	<brief_title>European Observational Study Enzalutamide Metastatic Castration Resistant Prostate Cancer ( mCRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men mCRPC prescribe enzalutamide part standard clinical practice Patients follow exclude study participation France : Patients previously treat abiraterone acetate ( Zytiga® ) docetaxel chemotherapy . Patients previously treat cabazitaxel ( Jevtana® ) Patients previously treat Xtandi® Patients take part interventional clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Metastatic castration resistant prostate cancer</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Xtandi</keyword>
</DOC>